REFERENCES
1. Parkinson J. An essay on the shaking palsy. Sherwood, Nelly and Jones 1817.
3. Mhyre TR, Boyd JT, Hamill RW, Maguire-Zeiss KA. Parkinson’s disease. Subcell Biochem 2012;65:389-455.
4. Vijayakumar D, Jankovic J. Drug-induced dyskinesia, Part 1: treatment of levodopa-induced dyskinesia. Drugs 2016;76:759-777.
5. Chaudhuri KR, Healy DG, Schapira AH. National Institute for Clinical E. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 2006;5:235-45.
6. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007;22:1689-707; quiz 1837.
8. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013;153:1194-217.
9. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 2000;3:1301-6.
10. Hernandez DG, Reed X, Singleton AB. Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. J Neurochem 2016;139 Suppl 1:59-74.
11. Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson’s disease. Lancet Neurol 2020;19:170-8.
12. Lerner TN, Shilyansky C, Davidson TJ, et al. Intact-brain analyses reveal distinct information carried by SNc dopamine subcircuits. Cell 2015;162:635-47.
13. Menegas W, Bergan JF, Ogawa SK, et al. Dopamine neurons projecting to the posterior striatum form an anatomically distinct subclass. Elife 2015;4:e10032.
14. Poulin JF, Zou J, Drouin-Ouellet J, Kim KY, Cicchetti F, Awatramani RB. Defining midbrain dopaminergic neuron diversity by single-cell gene expression profiling. Cell Rep 2014;9:930-43.
15. Liu G, Yu J, Ding J, et al. Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation. J Clin Invest 2014;124:3032-46.
16. Evans RC, Zhu M, Khaliq ZM. Dopamine inhibition differentially controls excitability of substantia nigra dopamine neuron subpopulations through T-type calcium channels. J Neurosci 2017;37:3704-20.
17. Hook PW, McClymont SA, Cannon GH, et al. Single-cell RNA-Seq of mouse dopaminergic neurons informs candidate gene selection for sporadic Parkinson disease. Am J Hum Genet 2018;102:427-46.
18. Przedborski S. The two-century journey of Parkinson disease research. Nat Rev Neurosci 2017;18:251-9.
19. Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. J Neurochem 2016;139 Suppl 1:318-24.
21. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-75.
22. Nelson AB, Kreitzer AC. Reassessing models of basal ganglia function and dysfunction. Annu Rev Neurosci 2014;37:117-35.
23. Bentivoglio M, Morelli M. The organization and circuits of mesencephalic dopaminergic neurons and the distribution of dopamine receptors in the brain. Dopamine 2005;21:1-107.
24. Weisenhorn DM, Giesert F, Wurst W. Diversity matters - heterogeneity of dopaminergic neurons in the ventral mesencephalon and its relation to Parkinson’s Disease. J Neurochem 2016;139 Suppl 1:8-26.
25. Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 1988;334:345-8.
26. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain 1999;122 (Pt 8):1437-48.
27. Hegarty SV, Sullivan AM, O’Keeffe GW. Midbrain dopaminergic neurons: a review of the molecular circuitry that regulates their development. Dev Biol 2013;379:123-38.
28. Smidt MP, Burbach JP. Terminal differentiation ofmesodiencephalic dopaminergic neurons: the role of Nurr1 and Pitx3. Adv Exp Med Biol 2009;651:47-57.
29. Smidt MP. Molecular programming of mesodiencephalic dopaminergic neuronal subsets. Front Neuroanat 2017;11:59.
30. Schein JC, Hunter DD, Roffler-Tarlov S. Girk2 expression in the ventral midbrain, cerebellum, and olfactory bulb and its relationship to the murine mutation weaver. Dev Biol 1998;204:432-50.
31. Karschin C, Dissmann E, Stuhmer W, Karschin A. IRK(1-3) and GIRK(1-4) inwardly rectifying K+ channel mRNAs are differentially expressed in the adult rat brain. J Neurosci 1996;16:3559-70.
32. Parent A, Fortin M, Cote PY, Cicchetti F. Calcium-binding proteins in primate basal ganglia. Neurosci Res 1996;25:309-34.
33. Liang CL, Sinton CM, Sonsalla PK, German DC. Midbrain dopaminergic neurons in the mouse that contain calbindin-D28k exhibit reduced vulnerability to MPTP-induced neurodegeneration. Neurodegeneration 1996;5:313-8.
34. Yamada T, McGeer PL, Baimbridge KG, McGeer EG. Relative sparing in Parkinson’s disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res 1990;526:303-7.
35. Poulin JF, Gaertner Z, Moreno-Ramos OA, Awatramani R. Classification of midbrain dopamine neurons using single-cell gene expression profiling approaches. Trends Neurosci 2020;43:155-69.
36. Greene JG, Dingledine R, Greenamyre JT. Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiol Dis 2005;18:19-31.
37. Chung CY, Seo H, Sonntag KC, Brooks A, Lin L, Isacson O. Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 2005;14:1709-25.
38. Cai H, Liu G, Sun L, Ding J. Aldehyde Dehydrogenase 1 making molecular inroads into the differential vulnerability of nigrostriatal dopaminergic neuron subtypes in Parkinson’s disease. Transl Neurodegener 2014;3:27.
39. Wu J, Kung J, Dong J, et al. Distinct connectivity and functionality of aldehyde dehydrogenase 1a1-Positive nigrostriatal dopaminergic neurons in motor learning. Cell Rep 2019;28:1167-81.e1167.
40. Tasic B. Single cell transcriptomics in neuroscience: cell classification and beyond. Curr Opin Neurobiol 2018;50:242-9.
41. Zeng H, Sanes JR. Neuronal cell-type classification: challenges, opportunities and the path forward. Nat Rev Neurosci 2017;18:530-46.
42. Poulin JF, Tasic B, Hjerling-Leffler J, Trimarchi JM, Awatramani R. Disentangling neural cell diversity using single-cell transcriptomics. Nat Neurosci 2016;19:1131-1141.
43. La Manno G, Gyllborg D, Codeluppi S, et al. Molecular diversity of midbrain development in mouse, human, and stem cells. Cell 2016;167:566-80.e519.
44. Tiklova K, Bjorklund AK, Lahti L, et al. Single-cell RNA sequencing reveals midbrain dopamine neuron diversity emerging during mouse brain development. Nat Commun 2019;10:581.
45. Saunders A, Macosko EZ, Wysoker A, et al. Molecular diversity and specializations among the cells of the adult mouse brain. Cell 2018;174:1015-30.e1016.
46. Kramer DJ, Risso D, Kosillo P, Ngai J, Bateup HS. Combinatorial expression of Grp and Neurod6 defines dopamine neuron populations with distinct projection patterns and disease vulnerability. eNeuro 2018;5:ENEURO.0152-18.2018.
47. Björklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci 2007;30:194-202.
48. Haber SN. The place of dopamine in the cortico-basal ganglia circuit. Neuroscience 2014;282:248-57.
49. Haber SN, Knutson B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology 2010;35:4-26.
50. Gerfen CR, Herkenham M, Thibault J. The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J Neurosci 1987;7:3915-34.
51. Smith Y, Masilamoni J. The Substantia Nigra. Reference Module in Neuroscience and Biobehavioral Psychology. Elsevier; 2017.
52. Gerfen CR, Bolam JP. The Neuroanatomical Organization of the Basal Ganglia. Handbook of Basal Ganglia Structure and Function. Elsevier; 2010. p. 3-28.
53. Brimblecombe KR, Cragg SJ. The Striosome and matrix compartments of the striatum: a path through the labyrinth from neurochemistry toward function. ACS Chem Neurosci 2017;8:235-42.
54. Graybiel AM. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990;13:244-54.
55. Gerfen CR. The neostriatal mosaic: compartmentalization of corticostriatal input and striatonigral output systems. Nature 1984;311:461-4.
56. Herkenham M, Pert CB. Mosaic distribution of opiate receptors, parafascicular projections and acetylcholinesterase in rat striatum. Nature 1981;291:415-8.
57. Jimenez-Castellanos J, Graybiel AM. Subdivisions of the dopamine-containing A8-A9-A10 complex identified by their differential mesostriatal innervation of striosomes and extrastriosomal matrix. Neuroscience 1987;23:223-42.
58. Gerfen CR. The neostriatal mosaic: striatal patch-matrix organization is related to cortical lamination. Science 1989;246:385-8.
59. Eblen F, Graybiel AM. Highly restricted origin of prefrontal cortical inputs to striosomes in the macaque monkey. J Neurosci 1995;15:5999-6013.
60. Kincaid AE, Wilson CJ. Corticostriatal innervation of the patch and matrix in the rat neostriatum. J Comp Neurol 1996;374:578-92.
61. Crittenden JR, Graybiel AM. Basal Ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. Front Neuroanat 2011;5:59.
62. Langer LF, Graybiel AM. Distinct nigrostriatal projection systems innervate striosomes and matrix in the primate striatum. Brain Res 1989;498:344-50.
63. Gerfen CR, Baimbridge KG, Thibault J. The neostriatal mosaic: III. Biochemical and developmental dissociation of patch-matrix mesostriatal systems. J Neurosci 1987;7:3935-44.
64. Olson L, Seiger A, Fuxe K. Heterogeneity of striatal and limbic dopamine innervation: highly fluorescent islands in developing and adult rats. Brain Res 1972;44:283-8.
65. Tennyson VM, Barrett RE, Cohen G, Cote L, Heikkila R, Mytilineou C. The developing neostriatum of the rabbit: correlation of fluorescence histochemistry, electron microscopy, endogenous dopamine levels, and (3 H)dopamine uptake. Brain Res 1972;46:251-85.
66. Poulin JF, Caronia G, Hofer C, et al. Mapping projections of molecularly defined dopamine neuron subtypes using intersectional genetic approaches. Nat Neurosci 2018;21:1260-71.
67. Menegas W, Babayan BM, Uchida N, Watabe-Uchida M. Opposite initialization to novel cues in dopamine signaling in ventral and posterior striatum in mice. Elife 2017;6:e21886.
68. Williams SM, Goldman-Rakic P. Widespread origin of the primate mesofrontal dopamine system. Cerebral cortex 1998;8:321-45.
69. Lewis D, Sesack S. Chapter VI Dopamine systems in the primate brain. The Primate Nervous System, Part I. Elsevier; 1997. p. 263-375.
70. Fallon JH, Loughlin SE. Substantia nigra. Rat Nervous System 1995.
71. Watabe-Uchida M, Zhu L, Ogawa SK, Vamanrao A, Uchida N. Whole-brain mapping of direct inputs to midbrain dopamine neurons. Neuron 2012;74:858-73.
73. Wittmann BC, Schott BH, Guderian S, Frey JU, Heinze HJ, Duzel E. Reward-related FMRI activation of dopaminergic midbrain is associated with enhanced hippocampus-dependent long-term memory formation. Neuron 2005;45:459-67.
74. Matsumoto M, Hikosaka O. Two types of dopamine neuron distinctly convey positive and negative motivational signals. Nature 2009;459:837-41.
75. Bromberg-Martin ES, Matsumoto M, Hikosaka O. Dopamine in motivational control: rewarding, aversive, and alerting. Neuron 2010;68:815-34.
76. Redgrave P, Prescott TJ, Gurney K. The basal ganglia: a vertebrate solution to the selection problem? Neuroscience 1999;89:1009-23.
77. Horvitz JC. Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events. Neuroscience 2000;96:651-6.
78. Chiara G. Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. Behav Brain Res 2002;137:75-114.
79. Pezze MA, Feldon J. Mesolimbic dopaminergic pathways in fear conditioning. Prog Neurobiol 2004;74:301-20.
80. Lisman JE, Grace AA. The hippocampal-VTA loop: controlling the entry of information into long-term memory. Neuron 2005;46:703-13.
81. Redgrave P, Gurney K. The short-latency dopamine signal: a role in discovering novel actions? Nat Rev Neurosci 2006;7:967-75.
84. Matsumoto N, Hanakawa T, Maki S, Graybiel AM, Kimura M. Role of [corrected] nigrostriatal dopamine system in learning to perform sequential motor tasks in a predictive manner. J Neurophysiol 1999;82:978-98.
85. Gambhir H, Mathur R, Behari M. Progressive impairment in motor skill learning at 12 and 20 weeks post 6-OHDA- SNc lesion in rats. Parkinsonism Relat Disord 2011;17:476-8.
86. Nomoto K, Schultz W, Watanabe T, Sakagami M. Temporally extended dopamine responses to perceptually demanding reward-predictive stimuli. J Neurosci 2010;30:10692-702.
87. Mirenowicz J, Schultz W. Preferential activation of midbrain dopamine neurons by appetitive rather than aversive stimuli. Nature 1996;379:449-51.
88. Zhang Y, Larcher KM, Misic B, Dagher A. Anatomical and functional organization of the human substantia nigra and its connections. Elife 2017;6:e26653.
89. Dagher A, Robbins TW. Personality, addiction, dopamine: insights from Parkinson’s disease. Neuron 2009;61:502-10.
90. Dalley JW, Robbins TW. Fractionating impulsivity: neuropsychiatric implications. Nat Rev Neurosci 2017;18:158-71.
91. Morris LS, Kundu P, Dowell N, et al. Fronto-striatal organization: Defining functional and microstructural substrates of behavioural flexibility. Cortex 2016;74:118-33.
92. Schiemann J, Schlaudraff F, Klose V, et al. K-ATP channels in dopamine substantia nigra neurons control bursting and novelty-induced exploration. Nat Neurosci 2012;15:1272-80.
93. Jin X, Costa RM. Start/stop signals emerge in nigrostriatal circuits during sequence learning. Nature 2010;466:457-62.
94. Schultz W. Multiple dopamine functions at different time courses. Annu Rev Neurosci 2007;30:259-88.
95. Yin HH, Ostlund SB, Balleine BW. Reward-guided learning beyond dopamine in the nucleus accumbens: the integrative functions of cortico-basal ganglia networks. Eur J Neurosci 2008;28:1437-48.
96. Cohen MX, Frank MJ. Neurocomputational models of basal ganglia function in learning, memory and choice. Behav Brain Res 2009;199:141-56.
97. Han JS, McMahan RW, Holland P, Gallagher M. The role of an amygdalo-nigrostriatal pathway in associative learning. J Neurosci 1997;17:3913-9.
98. Lee HJ, Groshek F, Petrovich GD, Cantalini JP, Gallagher M, Holland PC. Role of amygdalo-nigral circuitry in conditioning of a visual stimulus paired with food. J Neurosci 2005;25:3881-8.
99. El-Amamy H, Holland PC. Dissociable effects of disconnecting amygdala central nucleus from the ventral tegmental area or substantia nigra on learned orienting and incentive motivation. Eur J Neurosci 2007;25:1557-67.
100. Hall J, Parkinson JA, Connor TM, Dickinson A, Everitt BJ. Involvement of the central nucleus of the amygdala and nucleus accumbens core in mediating Pavlovian influences on instrumental behaviour. Eur J Neurosci 2001;13:1984-92.
101. Corbit LH, Balleine BW. Double dissociation of basolateral and central amygdala lesions on the general and outcome-specific forms of pavlovian-instrumental transfer. J Neurosci 2005;25:962-70.
102. Ikemoto S. Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res Rev 2007;56:27-78.
103. Roeper J. Dissecting the diversity of midbrain dopamine neurons. Trends Neurosci 2013;36:336-42.
104. Morales M, Margolis EB. Ventral tegmental area: cellular heterogeneity, connectivity and behaviour. Nat Rev Neurosci 2017;18:73-85.
105. Lammel S, Ion Daniela I, Roeper J, Malenka Robert C. Projection-specific modulation of dopamine neuron synapses by aversive and rewarding stimuli. Neuron 2011;70:855-62.
106. Carmichael K, Evans RC, Lopez E, et al. Function and regulation of ALDH1A1-positive nigrostriatal dopaminergic neurons in motor control and Parkinson’s disease. Front Neural Circuits 2021;15:644776.
107. Marchitti SA, Deitrich RA, Vasiliou V. Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol Rev 2007;59:125-50.
108. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114 (Pt 5):2283-301.
109. Sgobio C, Wu J, Zheng W, et al. Aldehyde dehydrogenase 1-positive nigrostriatal dopaminergic fibers exhibit distinct projection pattern and dopamine release dynamics at mouse dorsal striatum. Sci Rep 2017;7:5283.
110. Pan J, Yu J, Sun L, et al. ALDH1A1 regulates postsynaptic mu-opioid receptor expression in dorsal striatal projection neurons and mitigates dyskinesia through transsynaptic retinoic acid signaling. Sci Rep 2019;9:3602.
111. Evans RC, Twedell EL, Zhu M, Ascencio J, Zhang R, Khaliq ZM. Functional dissection of basal ganglia inhibitory inputs onto substantia nigra dopaminergic neurons. Cell Rep 2020;32:108156.
112. Graves SM, Xie Z, Stout KA, et al. Dopamine metabolism by a monoamine oxidase mitochondrial shuttle activates the electron transport chain. Nat Neurosci 2020;23:15-20.
113. Nair-Roberts RG, Chatelain-Badie SD, Benson E, White-Cooper H, Bolam JP, Ungless MA. Stereological estimates of dopaminergic, GABAergic and glutamatergic neurons in the ventral tegmental area, substantia nigra and retrorubral field in the rat. Neuroscience 2008;152:1024-31.
114. Taylor SR, Badurek S, Dileone RJ, Nashmi R, Minichiello L, Picciotto MR. GABAergic and glutamatergic efferents of the mouse ventral tegmental area. J Comp Neurol 2014;522:3308-34.
115. Breton JM, Charbit AR, Snyder BJ, et al. Relative contributions and mapping of ventral tegmental area dopamine and GABA neurons by projection target in the rat. J Comp Neurol 2019;527:916-41.
116. Fu Y, Paxinos G, Watson C, Halliday GM. The substantia nigra and ventral tegmental dopaminergic neurons from development to degeneration. J Chem Neuroanat 2016;76:98-107.
117. Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson’s disease. Mov Disord 2014;29:634-50.
118. Watson GS, Leverenz JB. Profile of cognitive impairment in Parkinson’s disease. Brain Pathol 2010;20:640-5.
119. Lanciego JL, Luquin N, Obeso JA. Functional neuroanatomy of the basal ganglia. Cold Spring Harb Perspect Med 2012;2:a009621.
120. Settell ML, Testini P, Cho S, et al. Functional circuitry effect of ventral tegmental area deep brain stimulation: imaging and neurochemical evidence of mesocortical and mesolimbic pathway modulation. Front Neurosci 2017;11:104.
121. Ballard IC, Murty VP, Carter RM, MacInnes JJ, Huettel SA, Adcock RA. Dorsolateral prefrontal cortex drives mesolimbic dopaminergic regions to initiate motivated behavior. J Neurosci 2011;31:10340-6.
122. Hauser TU, Eldar E, Dolan RJ. Separate mesocortical and mesolimbic pathways encode effort and reward learning signals. Proc Natl Acad Sci U S A 2017;114:E7395-404.
123. Halbout B, Marshall AT, Azimi A, et al. Mesolimbic dopamine projections mediate cue-motivated reward seeking but not reward retrieval in rats. Elife 2019;8:e43551.
124. Mingote S, Amsellem A, Kempf A, Rayport S, Chuhma N. Dopamine-glutamate neuron projections to the nucleus accumbens medial shell and behavioral switching. Neurochem Int 2019;129:104482.
125. Wanat MJ, Willuhn I, Clark JJ, Phillips PE. Phasic dopamine release in appetitive behaviors and drug addiction. Curr Drug Abuse Rev 2009;2:195-213.
126. Marinelli M, McCutcheon JE. Heterogeneity of dopamine neuron activity across traits and states. Neuroscience 2014;282:176-97.
127. Zhou Y, Bunney BS, Shi WX. Differential effects of cocaine on firing rate and pattern of dopamine neurons: role of alpha1 receptors and comparison with L-dopa and apomorphine. J Pharmacol Exp Ther 2006;317:196-201.
128. Fu Y, Yuan Y, Halliday G, Rusznak Z, Watson C, Paxinos G. A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse. Brain Struct Funct 2012;217:591-612.
129. Anderegg A, Poulin JF, Awatramani R. Molecular heterogeneity of midbrain dopaminergic neurons--moving toward single cell resolution. FEBS Lett 2015;589:3714-26.
130. Cai LX, Pizano K, Gundersen GW, et al. Distinct signals in medial and lateral VTA dopamine neurons modulate fear extinction at different times. Elife 2020;9:e54936.
131. Beier KT, Steinberg EE, DeLoach KE, et al. Circuit architecture of VTA dopamine neurons revealed by systematic input-output mapping. Cell 2015;162:622-34.
132. Del-Fava F, Hasue RH, Ferreira JG, Shammah-Lagnado SJ. Efferent connections of the rostral linear nucleus of the ventral tegmental area in the rat. Neuroscience 2007;145:1059-76.
133. Vaaga CE, Borisovska M, Westbrook GL. Dual-transmitter neurons: functional implications of co-release and co-transmission. Curr Opin Neurobiol 2014;29:25-32.
134. Lammel S, Lim BK, Ran C, et al. Input-specific control of reward and aversion in the ventral tegmental area. Nature 2012;491:212-7.
135. Lammel S, Lim BK, Malenka RC. Reward and aversion in a heterogeneous midbrain dopamine system. Neuropharmacology 2014;76 Pt B:351-9.
136. Alberico SL, Cassell MD, Narayanan NS. The vulnerable ventral tegmental area in Parkinson’s disease. Basal Ganglia 2015;5:51-5.
137. Fahn S. Description of Parkinson’s disease as a clinical syndrome. Ann N Y Acad Sci 2003;991:1-14.
138. Zampese E, Galtieri D, Schumacker P, Surmeier D. Determinants of Selective Vulnerability of Dopamine Neurons in Parkinson's Disease. Handbook of Basal Ganglia Structure and Function, Second Edition. Elsevier; 2016. p. 821-37.
139. Bisaglia M, Filograna R, Beltramini M, Bubacco L. Are dopamine derivatives implicated in the pathogenesis of Parkinson’s disease? Ageing Res Rev 2014;13:107-14.
140. Fahn S, Jankovic J, Hallett M. Current concepts on the etiology and pathogenesis of Parkinson disease. Principles and Practice of Movement Disorders. Elsevier; 2011. p. 93-118.
141. Alter SP, Lenzi GM, Bernstein AI, Miller GW. Vesicular integrity in Parkinson’s disease. Curr Neurol Neurosci Rep 2013;13:362.
142. Sanders LH, Timothy Greenamyre J. Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. Free Radic Biol Med 2013;62:111-20.
143. Asanuma M, Miyazaki I, Diaz-Corrales FJ, Ogawa N. Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson’s disease and neurotoxin-induced parkinsonism. Acta Med Okayama 2004;58:221-33.
144. Wang N, Wang Y, Yu G, Yuan C, Ma J. Quinoprotein adducts accumulate in the substantia nigra of aged rats and correlate with dopamine-induced toxicity in SH-SY5Y cells. Neurochem Res 2011;36:2169-75.
145. Segura-Aguilar J, Paris I, Munoz P, Ferrari E, Zecca L, Zucca FA. Protective and toxic roles of dopamine in Parkinson’s disease. J Neurochem 2014;129:898-915.
146. Zucca FA, Basso E, Cupaioli FA, et al. Neuromelanin of the human substantia nigra: an update. Neurotox Res 2014;25:13-23.
147. Sulzer D, Bogulavsky J, Larsen KE, et al. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci U S A 2000;97:11869-74.
148. Sulzer D, Zecca L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res 2000;1:181-95.
149. Zecca L, Zucca FA, Wilms H, Sulzer D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 2003;26:578-80.
150. Mann DM, Yates PO. Possible role of neuromelanin in the pathogenesis of Parkinson’s disease. Mech Ageing Dev 1983;21:193-203.
151. Mosharov EV, Staal RG, Bove J, et al. Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J Neurosci 2006;26:9304-11.
152. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001;294:1346-9.
153. Rochet JC, Outeiro TF, Conway KA, et al. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson’s disease. J Mol Neurosci 2004;23:23-34.
154. Sulzer D. Clues to how alpha-synuclein damages neurons in Parkinson’s disease. Mov Disord 2010;25 Suppl 1:S27-31.
155. Martinez-Vicente M, Talloczy Z, Kaushik S, et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008;118:777-88.
156. Burke WJ, Kumar VB, Pandey N, et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta neuropathologica 2008;115:193-203.
157. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson’s disease: evidence supporting it. Ann Neurol 1992;32:804-12.
158. Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 2013;136:2419-31.
159. Koppaka V, Thompson DC, Chen Y, et al. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacol Rev 2012;64:520-39.
160. Burke RE. Intracellular signalling pathways in dopamine cell death and axonal degeneration. Prog Brain Res 2010;183:79-97.
161. Goldstein DS, Kopin IJ, Sharabi Y. Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Pharmacol Ther 2014;144:268-82.
162. Grunblatt E, Ruder J, Monoranu CM, Riederer P, Youdim MB, Mandel SA. Differential alterations in metabolism and proteolysis-related proteins in human Parkinson’s disease substantia nigra. Neurotox Res 2017;33:560-8.
163. Wey MC, Fernandez E, Martinez PA, Sullivan P, Goldstein DS, Strong R. Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson’s disease. PloS one 2012;7:e31522.
164. Fan HH, Guo Q, Zheng J, et al. ALDH1A1 genetic variations may modulate risk of Parkinson’s disease in Han Chinese Population. Front Neurosci 2021;15:620929.
165. Fitzmaurice AG, Rhodes SL, Lulla A, et al. Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease. Proc Natl Acad Sci U S A 2013;110:636-41.
167. Garcia-Reitbock P, Anichtchik O, Bellucci A, et al. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson’s disease. Brain 2010;133:2032-44.
168. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-80.
169. Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011;72:57-71.
171. Groves PM, Linder JC, Young SJ. 5-hydroxydopamine-labeled dopaminergic axons: three-dimensional reconstructions of axons, synapses and postsynaptic targets in rat neostriatum. Neuroscience 1994;58:593-604.
172. Matsuda W, Furuta T, Nakamura KC, et al. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J Neurosci 2009;29:444-53.
173. Prensa L, Parent A. The nigrostriatal pathway in the rat: A single-axon study of the relationship between dorsal and ventral tier nigral neurons and the striosome/matrix striatal compartments. J Neurosci 2001;21:7247-60.
174. Bolam JP, Pissadaki EK. Living on the edge with too many mouths to feed: why dopamine neurons die. Mov Disord 2012;27:1478-83.
175. Pissadaki EK, Bolam JP. The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson’s disease. Front Comput Neurosci 2013;7:13.
176. Ashrafi G, Schlehe JS, LaVoie MJ, Schwarz TL. Mitophagy of damaged mitochondria occurs locally in distal neuronal axons and requires PINK1 and Parkin. J Cell Biol 2014;206:655-70.
177. Vos KJ, Grierson AJ, Ackerley S, Miller CC. Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci 2008;31:151-73.
178. Millecamps S, Julien JP. Axonal transport deficits and neurodegenerative diseases. Nat Rev Neurosci 2013;14:161-76.
179. Morfini GA, Burns M, Binder LI, et al. Axonal transport defects in neurodegenerative diseases. J Neurosci 2009;29:12776-86.
180. Salinas S, Bilsland LG, Schiavo G. Molecular landmarks along the axonal route: axonal transport in health and disease. Curr Opin Cell Biol 2008;20:445-53.
181. Surmeier DJ, Ding J, Day M, Wang Z, Shen W. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 2007;30:228-35.
182. Chan CS, Guzman JN, Ilijic E, et al. ‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease. Nature 2007;447:1081-6.
183. Grace AA, Bunney BS. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons--3. Evidence for electrotonic coupling. Neuroscience 1983;10:333-48.
184. Guzman JN, Sanchez-Padilla J, Chan CS, Surmeier DJ. Robust pacemaking in substantia nigra dopaminergic neurons. J Neurosci 2009;29:11011-9.
185. Neuhoff H, Neu A, Liss B, Roeper J. I(h) channels contribute to the different functional properties of identified dopaminergic subpopulations in the midbrain. J Neurosci 2002;22:1290-302.
186. Puopolo M, Raviola E, Bean BP. Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. J Neurosci 2007;27:645-56.
187. Wilson CJ, Callaway JC. Coupled oscillator model of the dopaminergic neuron of the substantia nigra. J Neurophysiol 2000;83:3084-100.
188. Grace AA, Bunney BS. The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci 1984;4:2866-76.
189. Overton PG, Clark D. Burst firing in midbrain dopaminergic neurons. Brain Res Brain Res Rev 1997;25:312-34.
190. Grace AA, Bunney BS. The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 1984;4:2877-90.
191. Baughman JM, Perocchi F, Girgis HS, et al. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. Nature 2011;476:341-5.
192. Stefani D, Raffaello A, Teardo E, Szabo I, Rizzuto R. A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature 2011;476:336-40.
193. Griffiths EJ, Rutter GA. Mitochondrial calcium as a key regulator of mitochondrial ATP production in mammalian cells. Biochim Biophys Acta 2009;1787:1324-33.
194. McCormack JG, Denton RM. Mitochondrial Ca2+ transport and the role of intramitochondrial Ca2+ in the regulation of energy metabolism. Dev Neurosci 1993;15:165-73.
195. McCormack JG, Halestrap AP, Denton RM. Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol Rev 1990;70:391-425.
196. Scheibye-Knudsen M, Mitchell SJ, Fang EF, et al. A high-fat diet and NAD(+) activate Sirt1 to rescue premature aging in cockayne syndrome. Cell Metab 2014;20:840-55.
198. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443:787-95.
199. Reeve AK, Krishnan KJ, Turnbull D. Mitochondrial DNA mutations in disease, aging, and neurodegeneration. Ann N Y Acad Sci 2008;1147:21-9.
200. Follett J, Norwood SJ, Hamilton NA, et al. The Vps35 D620N mutation linked to Parkinson’s disease disrupts the cargo sorting function of retromer. Traffic 2014;15:230-44.
201. Nielsen MS, Vorum H, Lindersson E, Jensen PH. Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization. J Biol Chem 2001;276:22680-4.
202. Rcom-H’cheo-Gauthier A, Goodwin J, Pountney DL: Interactions between calcium and alpha-synuclein in neurodegeneration. Biomolecules 2014;4:795-811.
203. Foehring RC, Zhang XF, Lee JC, Callaway JC. Endogenous calcium buffering capacity of substantia nigral dopamine neurons. J Neurophysiol 2009;102:2326-33.
204. Subramaniam M, Althof D, Gispert S, et al. Mutant alpha-synuclein enhances firing frequencies in dopamine substantia nigra neurons by oxidative impairment of A-type potassium channels. J Neurosci 2014;34:13586-99.
205. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 1994;12:529-40.
206. Traynelis SF, Wollmuth LP, McBain CJ, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 2010;62:405-96.
207. Standaert DG, Testa CM, Penney JB Jr, Young AB. Alternatively spliced isoforms of the NMDAR1 glutamate receptor subunit: differential expression in the basal ganglia of the rat. Neurosci Lett 1993;152:161-4.
208. Morikawa H, Khodakhah K, Williams JT. Two intracellular pathways mediate metabotropic glutamate receptor-induced Ca2+ mobilization in dopamine neurons. J Neurosci 2003;23:149-57.
209. Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990;39:151-70.
210. Zecca L, Casella L, Albertini A, et al. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson’s disease. J Neurochem 2008;106:1866-75.
211. Zhang W, Phillips K, Wielgus AR, et al. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson’s disease. Neurotox Res 2011;19:63-72.
213. Phani S, Re DB, Przedborski S. The role of the innate immune system in ALS. Front Pharmacol 2012;3:150.
214. Narayanan NS, Rodnitzky RL, Uc EY. Prefrontal dopamine signaling and cognitive symptoms of Parkinson’s disease. Rev Neurosci 2013;24:267-78.
215. Winter C, von Rumohr A, Mundt A, et al. Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. Behav Brain Res 2007;184:133-41.
216. Faivre F, Sanchez-Catalan MJ, Dovero S, et al. Ablation of the tail of the ventral tegmental area compensates symptoms in an experimental model of Parkinson’s disease. Neurobiol Dis 2020;139:104818.
217. Guo L, Xiong H, Kim JI, et al. Dynamic rewiring of neural circuits in the motor cortex in mouse models of Parkinson’s disease. Nat Neurosci 2015;18:1299-309.
218. Petrou M, Kotagal V, Bohnen NI. An update on brain imaging in parkinsonian dementia. Imaging Med 2012;4:201-13.
219. Goldman JG, Stebbins GT, Bernard B, Stoub TR, Goetz CG, deToledo-Morrell L. Entorhinal cortex atrophy differentiates Parkinson’s disease patients with and without dementia. Mov Disord 2012;27:727-34.
220. McNamara CG, Dupret D. Two sources of dopamine for the hippocampus. Trends Neurosci 2017;40:383-4.
221. Narayanan NS, Land BB, Solder JE, Deisseroth K, DiLeone RJ. Prefrontal D1 dopamine signaling is required for temporal control. Proc Natl Acad Sci U S A 2012;109:20726-31.
222. Parker KL, Alberico SL, Miller AD, Narayanan NS. Prefrontal D1 dopamine signaling is necessary for temporal expectation during reaction time performance. Neuroscience 2013;255:246-54.
223. Parkinson GM, Dayas CV, Smith DW. Increased mitochondrial DNA deletions in substantia nigra dopamine neurons of the aged rat. Curr Aging Sci 2014;7:155-60.
224. Backman L, Farde L. Dopamine and cognitive functioning: brain imaging findings in Huntington’s disease and normal aging. Scand J Psychol 2001;42:287-96.
225. Kaasinen V, Rinne JO. Functional imaging studies of dopamine system and cognition in normal aging and Parkinson’s disease. Neurosci Biobehav Rev 2002;26:785-93.
226. Leranth C, Roth RH, Elswoth JD, Naftolin F, Horvath TL, Redmond DE. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: Implications for Parkinson’s disease and memory. J Neurosci 2000;20:8604-09.
228. Halliday GM, McCann H. The progression of pathology in Parkinson’s disease. Ann N Y Acad Sci 2010;1184:188-95.
229. Kanaan NM, Kordower JH, Collier TJ. Age-related changes in dopamine transporters and accumulation of 3-nitrotyrosine in rhesus monkey midbrain dopamine neurons: relevance in selective neuronal vulnerability to degeneration. Eur J Neurosci 2008;27:3205-15.
230. Sulzer D, Cragg SJ, Rice ME. Striatal dopamine neurotransmission: regulation of release and uptake. Basal Ganglia 2016;6:123-48.
231. Salvatore MF, Apparsundaram S, Gerhardt GA. Decreased plasma membrane expression of striatal dopamine transporter in aging. Neurobiol Aging 2003;24:1147-54.
232. Ishibashi K, Oda K, Ishiwata K, Ishii K. Comparison of dopamine transporter decline in a patient with Parkinson’s disease and normal aging effect. J Neurol Sci 2014;339:207-9.
233. Troiano AR, Schulzer M, de la Fuente-Fernandez R, et al. Dopamine transporter PET in normal aging: dopamine transporter decline and its possible role in preservation of motor function. Synapse 2010;64:146-51.
234. Branch SY, Sharma R, Beckstead MJ. Aging decreases L-type calcium channel currents and pacemaker firing fidelity in substantia nigra dopamine neurons. J Neurosci 2014;34:9310-8.
235. Chan CS, Gertler TS, Surmeier DJ. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson’s disease. Mov Disord 2010;25 Suppl 1:S63-70.
236. Venkateshappa C, Harish G, Mythri RB, Mahadevan A, Bharath MM, Shankar SK. Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson’s disease. Neurochem Res 2012;37:358-69.
237. Reeve A, Simcox E, Turnbull D. Ageing and Parkinson’s disease: why is advancing age the biggest risk factor? Ageing Res Rev 2014;14:19-30.
238. Trist BG, Hare DJ, Double KL. Oxidative stress in the aging substantia nigra and the etiology of Parkinson’s disease. Aging Cell 2019;18:e13031.
239. Noda S, Sato S, Fukuda T, Tada N, Hattori N. Aging-related motor function and dopaminergic neuronal loss in C57BL/6 mice. Mol Brain 2020;13:46.
240. McCormack AL, Di Monte DA, Delfani K, et al. Aging of the nigrostriatal system in the squirrel monkey. J Comp Neurol 2004;471:387-95.
241. Emborg ME, Ma SY, Mufson EJ, et al. Age‐related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol 1998;401:253-65.
242. Jiang C, Wan X, He Y, Pan T, Jankovic J, Le W. Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol 2005;191:154-62.
243. Chu Y, Le W, Kompoliti K, Jankovic J, Mufson EJ, Kordower JH. Nurr1 in Parkinson’s disease and related disorders. J Comp Neurol 2006;494:495-514.
244. Zetterstrom RH, Solomin L, Jansson L, Hoffer BJ, Olson L, Perlmann T. Dopamine neuron agenesis in Nurr1-deficient mice. Science 1997;276:248-50.
245. Chu Y, Kompoliti K, Cochran EJ, Mufson EJ, Kordower JH. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol 2002;450:203-14.
246. Ma SY, Ciliax BJ, Stebbins G, et al. Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra. J Comp Neurol 1999;409:25-37.
247. Murty VP, Shah H, Montez D, Foran W, Calabro F, Luna B. Age-related trajectories of functional coupling between the VTA and nucleus accumbens depend on motivational state. J Neurosci 2018;38:7420-7.
248. Backman L, Lindenberger U, Li SC, Nyberg L. Linking cognitive aging to alterations in dopamine neurotransmitter functioning: recent data and future avenues. Neurosci Biobehav Rev 2010;34:670-7.
249. Peterson AC, Zhang S, Hu S, Chao HH, Li CR. The effects of age, from young to middle adulthood, and gender on resting state functional connectivity of the dopaminergic midbrain. Front Hum Neurosci 2017;11:52.
